Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tivantinib PK in Hepatic Impairment
NCT02150733Phase 1Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Apr 2014
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tivantinib in solid tumor (advanced stage) (4 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Composite of plasma pharmacokinetic parameters of Tivantinib. Started Apr 2014; status: completed.
02
Drugs
tivantinib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT02150733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02150733.